Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals stock popped Friday after the FDA signed off on its obesity drug for patients with a rare, hunger-spiking disease.